Overall AGEN gets a fundamental rating of 2 out of 10. We evaluated AGEN against 525 industry peers in the Biotechnology industry. Both the profitability and financial health of AGEN have multiple concerns. AGEN has a valuation in line with the averages, but it does not seem to be growing.

Quickly go to:

1. Profitability

2. Health

3. Growth

4. Valuation

5. Dividend

1. Profitability

1.1 Basic Checks

In the past year AGEN has reported negative net income.
AGEN had a negative operating cash flow in the past year.
In the past 5 years AGEN always reported negative net income.
In the past 5 years AGEN reported 4 times negative operating cash flow.

1.2 Ratios

The Return On Assets of AGEN (-15.13%) is better than 79.62% of its industry peers.

		Industry Rank	Sector Rank
ROA	-15.13%
ROE	N/A
ROIC	N/A

ROA(3y)-77.38%

ROA(5y)-64.35%

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

With an excellent Gross Margin value of 98.93%, AGEN belongs to the best of the industry, outperforming 98.29% of the companies in the same industry.
AGEN's Gross Margin has been stable in the last couple of years.
AGEN does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	98.93%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y0.24%

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

AGEN does not have a ROIC to compare to the WACC, probably because it is not profitable.
AGEN has more shares outstanding than it did 1 year ago.
The number of shares outstanding for AGEN has been increased compared to 5 years ago.
AGEN has a worse debt/assets ratio than last year.

2.2 Solvency

AGEN has an Altman-Z score of -14.09. This is a bad value and indicates that AGEN is not financially healthy and even has some risk of bankruptcy.
AGEN has a worse Altman-Z score (-14.09) than 78.67% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	N/A
Debt/FCF	N/A
Altman-Z	-14.09

ROIC/WACCN/A

WACC5.95%

2.3 Liquidity

AGEN has a Current Ratio of 0.47. This is a bad value and indicates that AGEN is not financially healthy enough and could expect problems in meeting its short term obligations.
With a Current ratio value of 0.47, AGEN is not doing good in the industry: 90.48% of the companies in the same industry are doing better.
AGEN has a Quick Ratio of 0.47. This is a bad value and indicates that AGEN is not financially healthy enough and could expect problems in meeting its short term obligations.
AGEN's Quick ratio of 0.47 is on the low side compared to the rest of the industry. AGEN is outperformed by 89.90% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	0.47
Quick Ratio	0.47

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

AGEN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 81.05%, which is quite impressive.
Looking at the last year, AGEN shows a very negative growth in Revenue. The Revenue has decreased by -33.41% in the last year.
AGEN shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -7.17% yearly.

EPS 1Y (TTM)81.05%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%162.99%

Revenue 1Y (TTM)-33.41%

Revenue growth 3Y-29.53%

Revenue growth 5Y-7.17%

Sales Q2Q%20.4%

3.2 Future

The Earnings Per Share is expected to grow by 15.41% on average over the next years. This is quite good.
The Revenue is expected to grow by 16.37% on average over the next years. This is quite good.

EPS Next Y91.44%

EPS Next 2Y46.39%

EPS Next 3Y22.51%

EPS Next 5Y15.41%

Revenue Next Year0.26%

Revenue Next 2Y29.88%

Revenue Next 3Y4.37%

Revenue Next 5Y16.37%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

AGEN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
AGEN is valuated cheaply with a Price/Forward Earnings ratio of 2.12.
Based on the Price/Forward Earnings ratio, AGEN is valued cheaper than 99.62% of the companies in the same industry.
AGEN's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 25.98.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	2.12

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

AGEN's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
AGEN's earnings are expected to grow with 22.51% in the coming years. This may justify a more expensive valuation.